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Summary
Rapamycin, an inhibitor of mTOR kinase, increased median
lifespan of genetically heterogeneous mice by 23% (males) to
26% (females) when tested at a dose threefold higher than that
used in our previous studies; maximal longevity was also
increased in both sexes. Rapamycin increased lifespan more in
females than in males at each dose evaluated, perhaps reflecting
sexual dimorphism in blood levels of this drug. Some of the
endocrine and metabolic changes seen in diet-restricted mice are
not seen in mice exposed to rapamycin, and the pattern of
expression of hepatic genes involved in xenobiotic metabolism is
also quite distinct in rapamycin-treated and diet-restricted mice,
suggesting that these two interventions for extending mouse
lifespan differ in many respects.
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longevity; mouse; mTOR; rapamycin; xenobiotic metabolism.
Introduction
Rapamycin, an inhibitor of mTOR kinase, increases lifespan of genetically
heterogeneous UM-HET3 mice when given at a dose of 14.7 mg kg1 in
food from either 9 or 20 months of age (Harrison et al., 2009; Miller
et al., 2011). Genetic or pharmacologic inhibition of mTOR has been
shown to increase lifespan of yeast (Kaeberlein et al., 2005; Powers
et al., 2006), worms (Vellai et al., 2003) and flies (Kapahi et al., 2004),
suggesting that the link between TOR and aging may have deep
evolutionary roots. Rapamycin also extends mouse lifespan (i) when given
as a brief (6 week) treatment to aged C57BL/6 mice (Chen et al., 2009),
(ii) when given by subcutaneous injection to female mice carrying the
tumorigenic HER-2/neu transgenic mice (Anisimov et al., 2010), or (iii)
when administered by injection to female inbred 129/Sv mice (Anisimov
et al., 2011). Genetic knockout of S6 kinase 1, one of the mediators of
mTORC1 action, has been shown to increase lifespan of female (but not
of male) C57BL/6 mice (Selman et al., 2009), consistent with the
rapamycin studies. Although rapamycin can block function of both mTOR
complexes, differential inactivation of mTORC1 via hemizygous deletion
of both mTOR and mLST8 extends lifespan of female (but not of male)
mice on a background containing a mixture of C57BL/6 and 129S5 genes
(Lamming et al., 2012), suggesting that effects on TORC1 may be
particularly germane to control of aging and/or late-life lethal disease.
The mechanism or mechanisms through which rapamycin increases
mouse lifespan are still uncertain. Inhibitors of mTOR function can block
tumor growth directly (Hidalgo & Rowinsky, 2000), and it is plausible that
direct effects on tumorsmay contribute to lifespaneffects inmice, inwhich
tumors are the most frequent class of lethal illness (Miller & Chrisp, 2002;
Lipman et al., 2004). Enteric-released rapamycin-treated UM-HET3 mice,
however, showdecelerated rates of change in awide range of age-related
physiological and pathological endpoints (Wilkinson et al., 2012), sug-
gesting that the drug may be inhibiting at least some aspects of the aging
process in addition to any direct effects itmayhave on cancer cells. An anti-
aging effect is also themost likely pathway for lifespan extension inworms
and flies, in which neoplastic disease is uncommon as a cause of death.
Our reports on rapamycin emerged from a study conducted by the
Interventions Testing Program (ITP; http://www.nia.nih.gov/research/
dab/interventions-testing-program-itp), in which drugs are tested for
mouse longevity effects at three institutions using a shared protocol
(Miller et al., 2007; Nadon et al., 2008). A priori, results of drug efficacy
emerging from testing single doses of each test agent are likely to
underestimate the optimal effect of the drugs tested, because it is
unlikely that the dose chosen for the initial test is at the peak of the dose/
response curve. To test whether optimal effects may emerge from doses
higher, or lower, than the one used in the initial study, we exposed
cohorts of UM-HET3 mice to rapamycin at three doses, over a ninefold
range, as a step toward determining the optimal dose for lifespan
prolongation in mice. We also explored the idea (Kaeberlein & Kennedy,
2009) that the lifespan extension caused by lifelong dietary restriction
(DR) might also be due largely to inhibition of mTOR function, by
comparing features of DR mice to those of rapamycin-treated mice.
Results
Mice were given food containing encapsulated rapamycin at one of
three doses at age 9 months and followed until death to produce the
survival data shown in Fig. 1, which pools results from all three sites. All
three doses extended lifespan in females, with higher effects seen at the
higher doses. The two highest doses also extended lifespan in male mice.
Table 1 collects statistics from these pooled survival tables. The highest
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tested rapamycin dose increased median lifespan by 23% in males and
26% in females. Maximal lifespan, evaluated according to Wang et al.,
(2004) as the proportion of mice still alive at the age of 90% mortality in
the joint lifespan distribution, was increased significantly (P < 0.001) by
each of the three rapamycin doses in females and by the two higher
doses in males (P = 0.006 and P = 0.001). Cox regression, stratified by
site, showed a significant effect of dose (P < 0.001) for each sex and a
significant difference between males and females, also at P < 0.001.
We also evaluated rapamycin effects at each of the three test sites
independently, while recognizing that the lower number of mice at each
site leads to a major loss of statistical power. Figure S1 (Supporting
information) shows survival curves at each of the three test sites, and
Table S1 (Supporting information) shows the corresponding statistics for
each site. Rapamycin at 42 ppm led to a significant improvement in
survival, in males, at each site, as assessed by the log-rank procedure,
with median lifespan increasing between 7% (at TJL) and 31% (at UT).
The effect of 14 ppm was more variable, with effects ranging from a
21% increase at UT to a 10% decline in median lifespan at TJL; as noted
above, the primary endpoint, that is, a site-stratified log-rank test in the
pooled data set, was significant at P = 0.002 in males, confirming our
earlier report at this dose (Miller et al., 2011). Rapamycin at 4.7 ppm
was not effective in increasing male lifespan in the pooled data set,
although it did lead to significant lifespan extension (16%, P = 0.02) at
UM. In females, even the lowest dose of rapamycin led to a significant
survival benefit by the log-rank test and a significant result in the Wang/
Allison test at 90th percentile mortality, at each site. The highest dose led
to increases in median of 20%, 22%, and 31% at the three sites,
representing good consistency for lifespan experiments of this kind.
Rapamycin concentrations were evaluated by HPLC–tandem mass
spectroscopy (Livi et al., 2013) in whole blood taken from a separate set
of UM-HET3 mice exposed to rapamycin, at UT, for 5 months starting at
3 or 4 months of age. Blood concentrations were 7, 16, and
80 ng mL1 for females at rapamycin doses of 4.7, 14, and 42 ppm,
respectively, and the corresponding values in males were 6, 9, and
23 ng mL1, with N = 4–8 mice in each group (Fig. S2, left panel). A
two-factor ANOVA (sex and rapamycin dose) showed significant effects of
sex (P = 0.007), rapamycin (P = 0.003), and interaction (P = 0.03),
indicating that blood levels of rapamycin were higher in female than in
male mice, with steeper dose-dependent increases in blood levels seen in
females. In a separate experiment, UM-HET3 mice at UT, at 26 months
of age, were fasted overnight and then allowed access to food
containing rapamycin at 42 ppm for 1 h. Blood samples were then
taken at intervals for the next 6 h. The results, shown in Fig. S2
(Supporting information), right panel, show higher levels of rapamycin in
blood of female mice at each time point tested. Although such
differences might reflect differences in food consumption, we conclude
that female UM-HET3 mice are likely to have higher blood levels of
Table 1 Survival statistics pooled across sites
Median Median increase Log-rank P-value N 90th %ile age 90th %ile increase Wang/Allison
Males
Controls 807 300 1094
Rapamycin (4.7) 834 3 0.19 156 1162 6 0.23
Rapamycin (14) 909 13 0.0015 156 1180 8 0.003
Rapamycin (42) 992 23 <0.0001 156 1185 8 0.004
Females
Controls 896 280 1159
Rapamycin (4.7) 1043 16 <0.0001 136 1218 5 <0.0001
Rapamycin (14) 1086 21 <0.0001 136 1285 11 <0.0001
Rapamycin (42) 1132 26 <0.0001 136 1282 11 <0.0001
Comment: median increase and 90th percentile increase are with respect to the corresponding values in the pooled controls of the same sex. Log-rank P-values were
calculated with stratification by site. Wang/Allison test P-values (Wang et al., 2004) used the Fisher’s exact test to compare the counts of live and dead mice, added across
the three test sites, at the site-specific age of 10% survival for the relevant joint distribution.
Fig. 1 Survival curves at varying doses of rapamycin. Survival curves for male (top)
and female (bottom) mice exposed to varying doses of rapamycin from
9 months of age. Data are pooled across the three test sites. At the time of
analysis, fewer than 1% of the mice were still alive. Significance tests, median age,
age of 90% mortality, and numbers of mice are shown in Table 1.
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rapamycin than males, at any age, given equal doses of rapamycin in the
chow. A similar pattern of sexual dimorphism was noted in studies of
C57BL/6 mice and in a segregating (C57BL/6 9 C3H/HeJ) stock used a
control for studies of human alpha-synuclein (R. Strong and M. Javors,
unpublished data).
Maximum likelihood calculations were conducted to estimate fits to
the Gompertz parameterization for each of the rapamycin survival
tables. Figure S3 (Supporting information) shows both smoothed and
fitted results, for each sex, comparing control mice to those treated with
the highest dose of rapamycin, and parameter estimates are shown in
Table S2 (Supporting information). For the females at 42 ppm, the
estimate for the Gompertz ‘a’ (intercept) parameter, indicative of
underlying, age-independent mortality risk, is 20-fold lower in rapamycin
mice compared with controls (P < 0.05). Females exposed to rapamycin
at 4 and 14 ppm had intermediate values, not significantly different
from controls. The estimate for the Gompertz ‘b’ (slope) parameter, an
index of age-dependent change in mortality risk, is significantly higher in
females receiving rapamycin at 42 ppm. The implications of this are
uncertain, however, because in small data sets of this kind, early deaths
are few and tend to produce elevation of the slope parameter in
association with decreases in the intercept value. For males, as in
females, the highest rapamycin dose led to a significantly lower ‘a’
parameter, but for males, there were no significant drug effects on the
Gompertz slope. These estimates, for both sexes, should be interpreted
with caution, because the calculations do not adjust for site-to-site
variation, statistical power is low, and therefore, confidence intervals are
correspondingly wide.
Our standard protocol calls for the removal of all mice in cages in
which fighting has led to serious injuries; both dominant and nondom-
inant, that is, wounded, mice are removed from the protocol to prevent
over-representation of mice with specific personality characteristics. This
policy typically leads to the removal of approximately 0–5% of the cages
of male mice, and in the current cohort, only 1% of control male cages
were culled because of fighting. We noted, however, that the proportion
of male mice removed because of fighting was elevated in the group
exposed to the highest dose of rapamycin, leading to the removal of
11% of the cages at TJL, 18% at UM, and 22% at UT. We do not know
whether this higher incidence of serious fight wounds reflects changes in
behavior of dominant or nondominant animals, or rapamycin-mediated
interference with wound healing. A more detailed behavior analysis,
with controlled tests on wound healing rates, would help to address this
unexpected observation.
In principle, a drug might lead to longevity extension by making food
unpalatable, thus reducing food intake sufficiently to induce true DR.
Figure 2 shows weight at ages 6, 12, 18, and 24 months in rapamycin-
treated and control mice. A similar pattern of rapamycin effects was
seen at each of the three test sites (not shown), although weights of
males and females at UM were, as in all previous ITP cohorts, consistently
lower than weights of mice at the other two sites. The highest dose of
rapamycin leads to 16–20% lower body weight (at 18 and 24 months,
respectively) in female mice, but the other two doses reduce body
weight by only 1–4%, making it seems unlikely that the lifespan effects
represent caloric restriction per se. In males, weight is reduced by 11%
and 19% at the two highest rapamycin doses. When UM-HET3 mice are
exposed to lifelong dietary restriction, effects on weight and lifespan
were similar in both sexes (Flurkey et al., 2010). An MRI method was
used at the UT site to evaluate lean and fat mass in a small group of 9-
month-old mice (N = 5–8 mice of each sex for each rapamycin dose). In
males, the highest dose of rapamycin decreased the proportion of
weight due to fat (29.3% vs. 35.8%, P = 0.0002 by t-test). A similar
effect was seen in females (36.6% in treated mice vs. 43.4% in
controls), but did not reach statistical significance (P = 0.13). The results
are shown in Fig. S4 (Supporting information).
Figure 3 presents a series of endocrine and metabolic indices
evaluated in UM-HET3 mice exposed to rapamycin at 4 months of
age, at the middle dose of 14 ppm, in parallel to a cohort placed on a
40% DR diet at the same age. These mice were housed at UM and were
not part of the longevity cohort. Fasting insulin levels (panel A) were
significantly diminished by DR in both males and females; rapamycin did
not lead to significant alterations in fasting insulin in either sex. Fasting
glucose levels were significantly increased in the rapamycin-treated mice
(panel B). Plasma IGF-1 was reduced by DR in both sexes; rapamycin
showed a similar trend, but did not lead to a significant reduction in IGF-
1 in either sex (panel C). Thyroid hormone T4 was increased by DR, but
not by rapamycin (panel D). FGF-21, a hormone produced by the liver in
response to acute starvation (35), was dramatically lower in plasma of
the DR mice, consistent with observations in other stocks (A. Bartke, L. Y.
Sun and A. Spong, unpublished data); rapamycin, in contrast, led to a
significant elevation in FGF-21 in male mice and did not alter FGF-21 in
females (panel E). DR mice had lower leptin levels, consistent with the
known effects of DR on adiposity, but rapamycin did not cause a decline
in leptin (panel F). In addition, testis weight, as a proportion of body
weight in 12 month old males, is reduced by rapamycin (25% decline,
P = 0.04), but not by DR (11% increase, P = 0.5). The DR and rapamycin
mice differ significantly from one another (P < 0.004), for each of the
endpoints shown in Fig. 3, except IGF-1. It is clear from this survey that
the endocrine changes induced by 5 months of DR diet are in many ways
distinct from those produced by 5 months of exposure to rapamycin at
14 ppm.
A separate experiment conducted at the UT site evaluated glucose
tolerance in UM-HET3 mice exposed to rapamycin for one month
starting at 4 months of age. As shown in Fig. 4, glucose tolerance is
impaired in both sexes even at the lowest dose of rapamycin, with
further impairment seen in mice exposed to the highest rapamycin dose.
In a two-factor analysis of variance, the effects of sex and rapamycin
level were each significant at P < 0.0001, and there was a significant
interaction term (P = 0.003), showing that the effects of rapamycin on
glucose tolerance were more dramatic in males than in females. A
parallel study of glucose responses after insulin injection (not shown)
revealed that rapamycin-treated mice, in general, were mildly insulin
resistant. Interestingly, we also noted a paradoxical increase in plasma
Fig. 2 Weight changes in control and rapamycin-treated mice. Weights of
control and rapamycin-treated mice at varying ages. Rapamycin treatment was
initiated at 9 months of age. Points indicate mean values, pooled across the
three test sites, for groups of approximately 150 mice in each rapamycin group and
300 control mice.
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glucose in males injected with insulin at 14 or 42 ppm, which was not
seen in control males or in any of the female groups. It is possible that
the increase in glucose seen after insulin injection into rapamycin-treated
males reflects a response to the stress of injection, but additional work
would be needed to address this idea.
We also evaluated hepatic expression of 52 mRNAs encoding
enzymes involved in metabolism of xenobiotic chemicals and toxins
(‘XME’, xenobiotic metabolizing enzymes). Genes encoding XMEs are
frequently overexpressed in Caenorhabditis elegans mutants that show
increased lifespan (Melo & Ruvkun, 2012) and have been postulated
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Fig. 3 Metabolic status of dietary restriction (DR) and rapamycin-treated mice. Endocrine and metabolic endpoints in control, rapamycin-treated (at 14 ppm), and DR
mice evaluated in plasma at 9 months of age after an overnight fast. DR and rapamycin exposure were begun at 4 months of age. Each bar shows mean and standard error
of the mean for 8–10 animals of each sex. For insulin, IGF-1 and FGF-21, ANOVA indicated a significant difference between males and females, and thus, each sex was
analyzed separately. Sexes are pooled for the analyses of glucose, T4, and leptin. An asterisk indicates significant difference from control mice at P < 0.05. DR and Rapa mice
differed at P < 0.006 for each endpoint, except IGF-1, for which there was no significant difference.
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(Gems, 2007) to play a causal role in worm lifespan extension. Similarly,
many XME mRNAs are elevated in liver of male Ames dwarf mice
(Amador-Noguez et al., 2005), consistent with the idea that protection
against the toxic effect of ingested or endogenously produced chemicals
may play a role in the long life of this pituitary-deficient dwarf mouse. A
survey of a subset of XME genes in male mice has also shown elevation
of many of these mRNA in Snell dwarf and DR mice, as well as in
rapamycin-treated mice (Steinbaugh et al., 2012). These previous
reports, however, did not include data on female mice and focused on
the set of XME genes that were known to be expressed at higher levels
in female (control) mice than in males (Waxman & Holloway, 2009).
In the current study, we evaluated expression of XME mRNAs in liver
of DR, rapamycin-treated (14 ppm), and control mice at 12 months of
age, using a set of mRNAs that varied widely in the degree and direction
of sexual dimorphism. The gene expression data are shown in Table S3
(Supporting information) and represented graphically in Fig. 5. Panel A
of Fig. 5 compares rapamycin to control mice, and Panel B compares the
same genes in DR versus control mice. In each figure, genes that are
preferentially expressed in control females are shown at the left, and
genes preferentially expressed in control males are shown at the right.
Bars shown in blue indicate mRNA whose expression is increased by
rapamycin (Fig. 5A) or by DR (Fig. 5B), and bars shown in red represent
genes that decrease in the treated mice compared with controls. The
extent of the alteration is shown on a log2 scale; the largest effects
therefore exceed 210, or 1000-fold.
The effects of the two interventions on XME gene expression are
clearly quite distinct. There is a tendency for ‘female-dominant’ XME
genes to be diminished by rapamycin in females and increased by
rapamycin in males. ‘Male-dominant’ XME genes show the opposite
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Fig. 4 One-month exposure to rapamycin impairs glucose tolerance.
UM-HET3 mice, at 4 months of age, were placed onto diet containing the
indicated doses of rapamycin at UT and evaluated 1 month later for responses
to intraperitoneal glucose injection. N = 5 of each treatment group for each
sex. The upper panels show mean  SEM for plasma glucose at the indicated
times. The bottom panels show integrated area under the glucose curve as
mean  SEM; bars that share a letter code are not statistically significant by
t-test.
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Fig. 5 Expression of mRNA for liver genes involved in xenobiotic metabolism.
Effects of rapamycin (top panel) and DR diet (middle panel) on hepatic mRNA
levels for 52 genes related to xenobiotic metabolism. Top and middle panels:
mice were placed on rapamycin (14 ppm) or DR diet at 4 months of age and
euthanized at 12 months of age. There were six males and six females in the
control group and in each of the two treatment groups. All mice were housed at
UM. Data from treated female mice are shown in the top of each panel, bars
pointing upwards, and data from treated male mice are shown in the bottom half,
with bars pointing downwards. The length of each bar is shown on a log2 scale, as
the ratio of treated mice divided by control mice. Bars shown in blue are increases
compared with control, and bars shown in red are decreases compared with
control mice. Thus, a blue bar with a value of eight represents an increase of
28=256-fold above control levels, and a red bar with a value of eight represents a
decline of 256-fold below control levels. Dark blue and dark red bars show
genes for which the nominal (unadjusted) P-value is P < 0.05. Lighter blue and red
bars shown genes that do not reach this arbitrary significance threshold. The first
gene, for example, Sult2a2 (see Table S3), is increased by DR, slightly but
significantly, in both males and females, is dramatically increased (by 211.6 = 3100-
fold) by rapamycin in males, but shows a large (212.4 = 5400-fold), significant
decline in rapamycin-treated females. The cyan arrowheads point out the three
mRNA that are elevated by both DR and rapamycin in both sexes.The bottom
panel shows female/male ratios, for untreated UM-HET3 controls; genes at the left
are expressed at levels approximately 212-fold higher in female controls, and genes
at the right are expressed roughly 211-fold higher in male controls.
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pattern, tending to increase in females treated with rapamycin and to
decrease in rapamycin-treated males. For these sexually dimorphic
mRNA, then, rapamycin tends to diminish sexual disparities in both
males and females. There are, however, many XME that do not follow
this pattern, and large, significant effects are also seen among mRNAs
that show little or no sexual dimorphism. Only six of the 52 mRNAs show
(nominally) significant increases in both males and females exposed to
rapamycin, and only a single mRNA shows a significant decrease in both
sexes.
The pattern of XME expression in livers of DR mice bears some
resemblance to that seen after rapamycin, in that there is a tendency for
female-dominant genes to be increased in male mice and for male-
dominant genes to be increased in female mice after DR. Twenty of the
52 tested mRNA show significant increases in both sexes in response to
the DR diet, and one shows a significant decrease. Of these 21 DR-
modified XME mRNAs, only three show parallel changes in males and in
females exposed to rapamycin. These three are Cyp3a41, Aldh3a2, and
Gstt1 at positions 4, 27, and 34 on the plots. Additional work would be
needed to see whether levels of the corresponding proteins did or did
not show parallel changes. This survey, although limited, does not
support the hypothesis that elevation of mRNA for hepatic XME is a
feature of rapamycin exposure, or the idea that gene expression changes
induced by rapamycin closely parallel those seen after dietary restriction.
Discussion
Rapamycin at 42 ppm leads to 26% increase in median lifespan in
females and 23% in males, in each case larger than that seen in previous
or current cohorts exposed to lower doses. Survival of the longest-lived
10% of the cohort was increased by 11% in females and by 8% in
males, and the drug benefited male and female mice at each of the test
sites. It is possible that larger lifespan effects might be seen at still higher
doses of rapamycin, or in mice treated with rapamycin in combination
with one or more agents that work through other pathways. The
lifespan benefit is not accompanied, in either sex, by weight loss to the
degree typical of mice exposed to DR (Flurkey et al., 2010), and the two
lower doses increased female lifespan significantly without any apparent
effect on weight. The middle dose of rapamycin (14 ppm) is the same as
that used for an earlier, independent cohort (Miller et al., 2011). In the
previous paper, the change in median lifespan for females was 18% and
for males was 10%, averaged across the three test sites. In the current
data set, the average increase for females was also 18% and for males
was 5%, in reasonably good agreement with the initial report.
Rapamycin leads to a larger percentage increase in female longevity
than in males, even though female controls live longer than male
controls at TJL and UT. It seems likely that this differential effect, seen
now in three consecutive independent cohorts, reflects higher levels of
rapamycin in blood of female UM-HET3 mice compared with males given
equal amounts of rapamycin in food. Our data show higher levels in
young females at each of three rapamycin doses and higher levels in old
females at varying times after consumption of rapamycin-containing
food. Similar sex effects were noted in at least two other strains of mice
(M. Javors and R. Strong, unpublished data). But it is also likely that
males and females may differ in other ways in their response to
rapamycin. For one example, gene expression changes induced by
rapamycin in males differ radically from those produced in females, at
least with respect to XME genes evaluated in Fig. 5. Hypotheses related
to sex hormones, sexual dimorphism in immune tone, differences
between males and females in GH pulse height (Waxman & Holloway,
2009), and sex-specific differences in fat distribution can be evaluated in
future studies of rapamycin effect. Mutations that diminish GH
production (Brown-Borg et al., 1996) or activity of mTOR (Selman et al.,
2009) can in some cases produce stronger effects in females than in
mice, but this pattern is by no means universal (Ladiges et al., 2009).
Two other agents tested by the ITP, specifically nordihydroguaiaretic acid
(NDGA) (Strong et al., 2008) and acarbose (Harrison et al., 2013), also
show sex-specific effects on lifespan, but these two agents affect
lifespan in males preferentially. In addition, there is some evidence that
the nonfeminizing estrogen 17-a-estradiol may also augment lifespan
preferentially in male mice (Harrison et al., in press).
It seems likely that rapamycin-mediated increases in lifespan reflect
both broad spectrum antitumor effects as well as deceleration of aging
processes more generally. Terminal (end of life) necropsies conducted on
mice exposed to 14 ppm rapamycin from nine months of age suggested
that the spectrum of specific lethal illnesses, mostly neoplastic, was not
altered by rapamycin, even though the age at death was higher in the
treated mice compared with controls, suggesting a drug-induced
postponement of tumor induction, progression, or lethal effect (Miller
et al., 2011). Data from cross-sectional histopathology have also been
published for mice at each of the three rapamycin doses tested here,
euthanized at 22 months of age (Wilkinson et al., 2012), and showed
evidence for rapamycin-dependent improvement in age-associated
changes in liver, myocardial, endometrium, adrenal, and tendon, in
addition to suggestive (but not statistically significant) effects in ovary,
thyroid, and lung. Rapamycin also retarded age-dependent declines in
spontaneous in-cage activity (Miller et al., 2011; Wilkinson et al., 2012).
Brief treatment of 22-month-old C57BL/6 mice has been found to
improve turnover of hematopoietic stem cells and B-cell production in
the bone marrow and to improve responses to influenza vaccination,
sufficient to protect aged mice from lethal viral infection (Chen et al.,
2009). Rapamycin administered to mice prone to Alzheimer’s-like brain
pathology delays development of tau and amyloid-dependent pathol-
ogy, leads to improvements in cognitive function (Caccamo et al., 2010).
In addition, rapamycin can reverse age-dependent defects in cardiac
function (Flynn et al., 2013), and can protect against atherosclerotic
change in mice prone to such disease (Mueller et al., 2008). These
results argue that rapamycin can slow the effects of aging on many cell
and tissue types and suggest that postponement of lethal neoplasia
could be mediated by direct effects both on the tumor cells and on age-
sensitive antitumor defenses. There are, however, age-dependent
changes in male C57BL/6 mice which are not prevented by rapamycin,
and some of the protective effects of this drug appear to reflect
immediate benefits rather than delay in age-dependent change (Neff
et al., 2013).
The documented decline in TOR activity seen in DR rodents (Sun
et al., 2009) supports the idea (Kaeberlein & Kennedy, 2009) that lower
TOR function may be responsible for lifespan extension in both kinds of
mice. Our data do not disprove this idea, but they do document many
differences between DR and rapamycin effects on characteristics
postulated to play a role in age-dependent pathophysiology (Figs 3
and 4). Rapamycin does not lead to the decline in fasting insulin, leptin,
IGF-1, or FGF-21 or to the increase in T4 seen in UM-HET3 mice after
5 months of DR, but does cause an increase in fasting glucose not seen
in the DR animals. At this point, it is not known which changes, in which
cell(s), lead to slower aging in either DR or rapamycin-treated mice, so it
is not possible to know whether the two interventions alter aging
through shared mechanisms. We believe that our data do show,
however, that the effects of rapamycin, at the doses used, differ in some
ways from those produced by DR, making it less likely that the lifespan
effect is due simply to diminished calorie or nutrient intake. A detailed
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tabulation of the effects produced by rapamycin, various forms of dietary
restriction, other drugs that extend lifespan (Harrison et al., 2013), and
life-extending mutants may help direct experimental attention to specific
shared pathways.
There is now good evidence that rapamycin can alter glucose
metabolism after various times and levels of exposure in mice. For
example, in both young and old UM-HET3 mice, rapamycin treatment at
14 ppm for 3 weeks causes glucose intolerance and increased gluco-
neogenesis (Lamming et al., 2013). Chronic injection of rapamycin also
causes hepatic insulin resistance in young C57BL/6 mice and Sprague-
Dawley rats (Houde et al., 2010; Lamming et al., 2012). There is also
evidence that rapamycin is toxic to pancreatic b-cells both in vitro and in
vivo (Barlow et al., 2013). As increased insulin sensitivity is a notable
feature of longevity extension in pituitary dwarf mutants (Dominici et al.,
2002) and in DR rodents (Barzilai et al., 1998; Fok et al., 2013), the
deficit in glucose homeostasis consistently seen in rapamycin-treated
mice is unexpected and suggests that the lifespan benefit of this drug
might be extended still further by combination of rapamycin with an
insulin sensitizing agent like metformin. On the other hand, it is
interesting to note that we found the dose of rapamycin that extends
lifespan to the greatest degree (42 ppm) is also associated with the
largest deficits in glucose metabolism. The data in Fig. 4 indicate that the
loss of glucose tolerance is seen as early as 1 month after the start of
rapamycin treatment and is dose dependent. The rapamycin effect is
seen in both sexes, but is more dramatic in male mice, at least at this
time point. It is possible, although clearly speculative, that the more
dramatic loss of glucose control seen in males could contribute to the
lower lifespan effect produced by rapamycin in males. Males and
females also differ in that only in males does rapamycin produce a
paradoxical hyperglycemia after insulin injection (data not shown),
perhaps reflecting male-specific sensitivity to handling stress or insulin-
mediated stress.
The association between insulin sensitivity and longevity is still a
topic of active investigation. One recent study, for example, found that
increasing insulin sensitivity can lead to shorter lifespan in mice, and
the mice with reduced insulin sensitivity did not necessarily have
shorter lifespan (Nelson et al., 2012). The ITP group has initiated an
experiment to see whether the lifespan effect of rapamycin on UM-
HET3 mice is altered, in either direction, by administration of
metformin.
In addition, the effects of the two interventions on hepatic expression
of XME genes show little overlap in pattern or detail (Fig. 5). Our initial
working hypothesis, based on the prior observations and speculation
(Gems, 2007), was that many XME genes would be elevated in both
males and females of the DR and rapamycin groups. In addition, the idea
that TOR inhibition is a key feature of the DR longevity effect implied
that at least some subset of XME genes would be changed in parallel in
both treatment groups, and for both males and females. Neither of these
ideas receives much support from the data in Fig. 5. Only three of the 52
genes tested showed an elevation in both sexes of both treatment
groups. Sex-specific differences in the amplitude of pulses in serum
growth hormone levels have been shown (Waxman & Holloway, 2009)
to exert a major influence on hepatic expression of XME genes. Male
mice typically have higher peak levels and lower trough levels of GH than
females, leading to repression in males of many XME genes that are
strongly expressed in females. Studies of male Ames (Amador-Noguez
et al., 2005) and Snell (Steinbaugh et al., 2012) dwarf mice have shown
strong and consistent activation of XME genes, but focused largely on
genes that are expressed more highly in female controls; in retrospect,
these findings are plausibly interpreted as the loss of repression of
female-specific XME genes when GH pulses are obliterated in the male
pituitary mutants. Of the 10 mRNA with the highest ratio of female/male
expression in controls (see bottom panel of Fig. 5), all 10 are increased
by DR in males, as are seven of the ten in rapamycin-treated males. In
principle, this effect might indicate a loss of the GH-dependent
repression of XME expression in males. The observations in female
mice, however, complicate the story, in that many of these 10 genes are
also elevated in DR females, and six show a decline in females exposed to
rapamycin. Both DR and rapamycin tend to increase expression of male-
dominant genes in female mice and to decrease expression of these
same genes in male mice, but it is not clear how such neutralization of
the sexual dimorphism in XME expression might contribute to the
extension of both male and female lifespan seen in rapamycin-treated
and DR-treated (Flurkey et al., 2010) UM-HET3 mice. Data on expression
of XME genes in other models of delayed aging in mice may provide a
better understanding of the role, if any, of XME gene expression in the
control of mouse lifespan, but the current data give few hints of
common features, shared by the two interventions in both sexes, which
might contribute to the delay in aging and late-life diseases.
Rapamycin, like DR, slows many aspects of aging in UM-HET3 mice
(Wilkinson et al., 2012), delays cancer (Livi et al., 2013), and extends
lifespan. While we do not know how either intervention produces these
beneficial effects, it will be of great interest to learn whether rapamycin
and DR share one or more critical causal mechanisms or act through
different pathways. The growing availability of drugs, diets (Orentreich
et al., 1993), developmental interventions (Sun et al., 2009), and
mutations (Brown-Borg et al., 1996; Ladiges et al., 2009) that extend
mouse mean and maximal lifespan provides a battery of model systems
in which to look for pathways that may be shared among these different
anti-aging interventions.
Experimental procedures
Mice, husbandry, and survival data
Details of breeding and husbandry, including preparation of encapsu-
lated (enteric-released) rapamycin, have been described at length in
earlier papers (Miller et al., 2007, 2011; Strong et al., 2013), as have
results of both end of life (Miller et al., 2011) and midlife (Wilkinson
et al., 2012) necropsy analyses. In brief, genetically heterogeneous UM-
HET3 mice were produced by a cross between CByB6F1/J mothers (JAX
#100009) and C3D2F1/J fathers (JAX #100004), at each of three test
sites: the Jackson Laboratory (TJL), the University of Michigan (UM), or
the University of Texas Health Science Center at San Antonio (UT). They
were housed at three male mice or four female mice per cage from
weaning and at 9 months of age were given a diet containing
encapsulated rapamycin at 4.7, 14, or 42 ppm (mg of drug per kg of
food). Mice that died were not replaced, so cage density declined at
older ages. Cages were inspected daily. Date of death was noted for
mice found dead, and mice found to be so ill that they were expected to
die within the next 24–48 h were euthanized, with the date of
euthanasia taken as the date of death for life table calculations. At the
time of analysis, 532 control mice had died, and two control mice (0.4%)
were alive; 749 mice exposed to rapamycin had died, and 15 (1.9%)
were alive. In addition, five mice were removed prior to natural death
because of experimental accidents (for example, death during implan-
tation of ID tag); six were removed for humane reasons because of
dermatitis; 74 males were removed according to our protocol policy
which requires euthanasia of all mice in cages in which any mouse is
found to have extensive fight wounds (Miller et al., 2007); and 104
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mice, all at TJL, were removed for use in a separate study of immune
function.
Assessment of glucose and hormones in plasma
Mice at UM were fasted overnight (18 h), after which blood samples for
hormone measurements were collected via tail nick, without anesthesia,
using heparin as an anticoagulant. Samples were obtained between 8
and 10 am. Glucose levels were determined using a handheld glucom-
eter, and the plasma samples then stored at 80 °C prior to the
assessment of hormone concentrations. Plasma IGF-1 levels were
determined with a double-antibody RIA kit (Cat. # IGF-21, ALPCO,
Salem, NH, USA). For the IGF-1 RIA, the assay was run at one-quarter of
the manufacturer’s recommended protocol volumes. Plasma T4 levels
were quantified using a monoclonal solid-phase RIA kit (Cat. # 06B-
254011, MP Biomedicals, Orangeburg, NY, USA). For the T4 RIA, the
assay was run at 40% of the volumes stated in the manufacturer’s
protocol. Insulin levels were quantified via a two-site enzyme immuno-
assay kit (Cat. # 80-INSMSU-E01, ALPCO). Plasma leptin levels were
determined using an ELISA sandwich assay (Cat. # 90030, Crystal Chem
Inc., Downers Grove, IL, USA). Leptin samples were performed in two
batches, and a correction factor used to adjust the mean level in each
batch to the same level prior to further analysis. Plasma FGF-21 levels
were quantified using an ELISA sandwich assay. (Cat.# EZRMFGF21-26K,
Millipore, St. Charles, MO, USA). All samples were assayed in duplicate.
Glucose tolerance
UM-HET3 mice housed at UT were fed control, 4.7, 14, and 42 ppm
rapamycin diets starting at 4 months of age for 1 month. For the
glucose tolerance tests, mice were fasted 6 h (09:00–15:00) prior to
each test and then injected intraperitoneally with glucose (1.5 g kg1) in
saline. Blood glucose levels were measured at indicated time points from
tail vein bleeding by handheld glucometer (LifeScan, Milpitas CA, USA).
Area under curve (AUC) was calculated for each animal using the
trapezoid method.
Gene expression measurements
Liver was taken from mice at 12 months of age, after 8 months
exposure to control, rapamycin, or DR diets. Total RNA was isolated
from mouse livers using Trizol (Invitrogen, Carlsbad, CA, USA), cleaned
using the Qiagen RNeasy mini RNA cleanup protocol (Qiagen, Valencia,
CA, USA), and quantified using a Nanodrop ND-100. Total RNA was
then transcribed to cDNA using iScriptTMcDNA reverse transcription kits
(1708891; Bio-Rad, Hercules, CA, USA). Reverse transcription products
were amplified using Power SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA, USA) and PCR primers (Integrated DNA
Technologies, Coralville, IA, USA). RT–PCR was performed using ABI PRISM
sequence detection system instrument and software (Applied Biosys-
tems). Ct data, indicating the number of amplification cycles needed to
achieve threshold, were available from six male and six female mice per
treatment group. The effect of rapamycin or DR diet was estimated as
the difference between Ct for the mutant mouse and Ct for sex-
matched littermate controls, with a positive value in cases where
expression of the mRNA was increased by diet compared with control
animals. Because a change in one unit for Ct reflects a twofold change
in mRNA abundance, effect sizes in the figures and tables reflect powers
of 2. Thus, an effect size of 5 indicates an increase in mRNA
concentration of 25 = 32-fold.
Determination of rapamycin levels in plasma by tandem
HPLC-MS
This method has been described elsewhere (Livi et al., 2013).
Body composition
Fat and lean mass were evaluated by quantitative magnetic resonance
imaging (QMR) with the EchoMRI-3-in-1 system (Echo Medical System,
Houston, TX, USA), as described (Tinsley et al., 2004). The procedure
requires immobilizing the mice in plastic restrainer tubes without
sedation and takes <2 min per mouse.
Statistics
Survival curves were compared using the log-rank test, with stratifica-
tion by site for comparisons that pooled data across sites. Mice that had
been removed from the protocol, for example, because of an accident
or fighting, were treated as alive on the day of removal and lost to
follow up thereafter. Statements about maximal lifespan were based on
the method of (Wang et al., 2004), using Fisher’s exact test at the age
at which 90% of the mice in the pooled survival table had died. Point
estimates of mortality rates (ux) were obtained by pooling deaths and
censored observations into 2-week census intervals and calculating
ux = ln(px), where px is the probably of surviving through interval age
x. Parameter estimates for the Gompertz mortality model were obtained
using maximum likelihood analysis of actual (i.e., not pooled) observa-
tion times (Pletcher, 1999). For metabolic tests, two-factor ANOVA (sex,
treatment) was used to determine whether there was a significant
difference between males and females; if a sex effect was noted, then
the data were analyzed separately for each sex, and the data were
pooled for analysis if no sex effect was noted. Differences between
treated and control groups, or in some cases between DR and
rapamycin groups, were evaluated by t-test, and nominal P-values were
reported without adjustment for multiple comparisons. For the gene
expression studies, unadjusted Ct values (which are on a log2 scale)
were compared for each gene between control and treated mice, using
a t-test with no adjustments for multiple comparisons. Error bars shown
in the figures indicate standard errors of the mean, and all P-values
represent two-sided tests. Table S4 (Supporting information) provides
information on sensitivity and reproducibility of the hormone tests
shown in Fig. 3.
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